Older adults · Virginia
Studies for adults 50 and older in Virginia
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Charlottesville, VA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Arlington, VA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette);
Genentech, Inc.
- Location
- Lynchburg, VA + 14 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Falls Church, VA + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Hoffmann-La Roche
- Location
- Arlington, VA + 11 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Fairfax, VA + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Charlottesville, VA + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Charlottesville, VA + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd.
- Location
- Lynchburg, VA + 66 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Lynchburg, VA + 44 other US sites
- Eligibility basics
- Ages 60+
- Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
- Location
- Alexandria, VA + 10 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Richmond, VA + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Richmond, VA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Lynchburg, VA + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Vienna, VA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Lynchburg, VA + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 1/Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Skyline Therapeutics (US) Inc.
- Location
- Norfolk, VA + 2 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Roanoke, VA + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
GlaxoSmithKline
- Location
- Charlottesville, VA + 11 other US sites
- Eligibility basics
- Ages 65–85
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Lynchburg, VA + 77 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Novartis Pharmaceuticals
- Location
- Falls Church, VA + 29 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 2
Open-label Extension Study in Participants With Early Alzheimer's Disease
GlaxoSmithKline
- Location
- Fairfax, VA + 8 other US sites
- Eligibility basics
- Ages 50–85
- Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Edwards Lifesciences
- Location
- McLean, VA + 49 other US sites
- Eligibility basics
- Ages 65+
- RecruitingHealthy volunteers
Cooking Health-Oriented Meals to Prevent Dementia and Diabetes
Virginia Polytechnic Institute and State University
- Location
- Blacksburg, VA
- Eligibility basics
- Ages 50–75